Latest Commercial Revenue News

Aeris Environmental’s FY2026 annual report pairs international commercial progress with a $5.03 million operating cash drain, $9.22 million in net liabilities and an auditor-highlighted material uncertainty over its ability to continue as a going concern. The company says it will need extended related-party loan terms and further funding while converting its technology and chemicals pipeline into recurring revenue.

ClearVue Technologies reported just A$108,484 of FY2026 revenue against an A$11.86 million loss, while consuming A$8.69 million in operating cash. The solar-glazing developer says certifications, international partners and an 80-project pipeline have strengthened its platform, but the next test is converting those assets into cash revenue.

FBR has cut its annual loss dramatically and moved its first Mantis welding robot into commissioning, but year-end cash of just A$27,814 leaves the company dependent on fundraising, tax funding and successful delivery. Its audited accounts flag a material uncertainty over whether the robotics developer can continue as a going concern.

Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.

AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.

Green Technology Metals has cleared the environmental assessment for its Seymour lithium project, while a A$15.9 million capital raising leaves the company better placed to complete its definitive feasibility study. The next test is whether permitting, financing and Indigenous agreements can convert that progress into a Final Investment Decision in FY27.

Li-S Energy has narrowed its FY26 loss and reached several commercialisation milestones, including a 2C Power Cell, international shipping approvals and its first lithium foil sale. But the ASX battery developer still needs customer offtake and fresh funding before its proposed 1 GWh manufacturing expansion can become reality.

Temple & Webster delivered record FY26 revenue of $664.6 million and lifted underlying EBITDA by 28%, despite a sharp fall in statutory profit after tax. The online retailer is targeting EBITDA of $33 million to $40 million in FY27 as improved margins, exclusive products and adjacent categories do more of the heavy lifting.

Structural Monitoring Systems (ASX:SMN) delivered record FY26 revenue, a sharp lift in profit and $6.0 million of free cash flow as its avionics business outpaced contract manufacturing. The balance sheet is now free of bank debt, but the next leg of the story still depends on FAA approvals and converting CVM technology into commercial revenue.

Spacetalk Limited (ASX:SPA) has posted a sharply deeper FY26 loss and negative net assets, while its auditor flagged a material uncertainty over the company’s ability to continue as a going concern. The company says a $10 million post-year-end placement, note conversions and new telco agreements give its software-led strategy room to execute.

AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.